Incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): An updated systematic review of population-based reports from 2010 to 2023

被引:0
|
作者
Nordstrand, Magnus Andreas [1 ]
Lea, Dordi [2 ]
Soreide, Jon Arne [1 ,3 ]
机构
[1] Stavanger Univ Hosp, Dept Gastrointestinal Surg, N-4068 Stavanger, Norway
[2] Stavanger Univ Hosp, Dept Pathol, Stavanger, Norway
[3] Univ Bergen, Dept Clin Med, Bergen, Norway
关键词
gastroenteropancreatic neuroendocrine neoplasms; GEP-NENs; incidence; neuroendocrine neoplasms; population-based; TUMORS; SURVIVAL; EPIDEMIOLOGY; NETHERLANDS; IMMUNOHISTOCHEMISTRY; SYNAPTOPHYSIN; OUTCOMES;
D O I
10.1111/jne.70001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is a general perception that the incidence of neuroendocrine neoplasms (NENs) has been increasing. Nevertheless, reports of actual population-based studies are scarce, and pertinent data from some geographical regions still need to be available. In this systematic literature review of population-based studies, we aimed to evaluate the available data to provide updated figures on the incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Guided by the PRISMA 2020 statement reporting items for systematic reviews, this study conducted a systematic search using Ovid in the bibliographic databases Embase, Medline, and Web of Science Core Collection. Only incidence-reporting studies were included. In total, 847 articles were identified, and through a strict evaluation process using predefined inclusion and exclusion criteria, we found 19 papers that reported the general incidence of GEP-NENs from all sites. In addition, we considered another 15 papers that focused on the epidemiologic aspects of single-organ studies. While the incidence rates of GEP-NEN vary across similar countries, the general incidence of GEP-NEN has been increasing worldwide in recent decades. The incidence of GEP-NENs has increased worldwide over the last two decades, and reliable figures from new regions add to this pattern. Nevertheless, variations in the classification, grading, and reporting of GEP-NENs in various studies make direct comparisons difficult.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case–control study
    T. Feola
    G. Puliani
    F. Sesti
    R. Modica
    R. Centello
    R. Minotta
    G. Cannavale
    S. Di Meglio
    V. Di Vito
    R. Lauretta
    M. Appetecchia
    A. Colao
    A. Lenzi
    A. M. Isidori
    A. Faggiano
    E. Giannetta
    Journal of Endocrinological Investigation, 2022, 45 : 849 - 857
  • [22] Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data
    Abdel-Rahman, Omar
    Fouad, Mona
    TUMOR BIOLOGY, 2015, 36 (02) : 467 - 478
  • [23] CHROMOGRANIN A AS A MARKER IN THE FOLLOWUP OF GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NENS). A SYSTEMATIC REVIEW
    Rossi, R. E.
    Ciafardini, C.
    Conte, D.
    Sciola, V.
    Massironi, S.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E162 - E162
  • [24] Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study
    Feola, T.
    Puliani, G.
    Sesti, F.
    Modica, R.
    Centello, R.
    Minotta, R.
    Cannavale, G.
    Di Meglio, S.
    Di Vito, V.
    Lauretta, R.
    Appetecchia, M.
    Colao, A.
    Lenzi, A.
    Isidori, A. M.
    Faggiano, A.
    Giannetta, E.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (04) : 849 - 857
  • [25] Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) in the Czech NEN Registry 2009-2016: Histologic Spectrum and Clinicopathological Features
    Sedlackova, E.
    Barkmanova, J.
    Novak, J.
    Mandys, V
    NEUROENDOCRINOLOGY, 2018, 106 : 117 - 117
  • [26] Early Evaluation of Sunitinib in Treatment of Advanced Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) by CT Imaging: RECIST or Choi Criteria?
    Luo, Y.
    Chen, J.
    Li, Z. P.
    Feng, S. T.
    NEUROENDOCRINOLOGY, 2016, 103 : 82 - 82
  • [27] Chromogranin A as a Marker in the Follow-up of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). A Systematic Review
    Rossi, R. E.
    Ciafardini, C.
    Conte, D.
    Sciola, V
    Massironi, S.
    NEUROENDOCRINOLOGY, 2018, 106 : 163 - 163
  • [28] Classification of Lung Neuroendocrine Neoplasms (Lung-NENs) According to WHO 2010 for Gastroenteropancreatic NENs (GEP-NENs) Has Prognostic Relevance and Includes Lung-NETs G3
    Kasajima, A.
    Oka, N.
    Ishida, H.
    Sakurada, A.
    Kameya, T.
    Konukiewitz, B.
    Kloeppel, G.
    Weichert, W.
    Ishikawa, Y.
    Okada, Y.
    Sasano, H.
    NEUROENDOCRINOLOGY, 2017, 105 : 133 - 133
  • [29] The Correlation between 68Ga-DOTATATE PET/CT Results and Tumor Proliferation in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
    Yu, J.
    Li, J.
    Lu, M.
    Zhang, P.
    Yang, Z.
    NEUROENDOCRINOLOGY, 2018, 106 : 266 - 266
  • [30] Long-Term Outcomes and Prognostic Factors of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): An Update of a Large National Registry (RGETNE)
    Jimenez-Fonseca, P.
    Castano, A.
    Pi Barrio, J. J.
    Alonso, V
    Custodio, A.
    Marazuela, M.
    Llanos, M.
    Diaz, J. A.
    Lopez, C.
    Alonso, T.
    Blanco, C.
    La Casta, A.
    Alvarez-Escola, C.
    Alcazar, V
    Capdevila, J.
    NEUROENDOCRINOLOGY, 2017, 105 : 81 - 81